1. Home
  2. XGN vs GANX Comparison

XGN vs GANX Comparison

Compare XGN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XGN
  • GANX
  • Stock Information
  • Founded
  • XGN N/A
  • GANX 2017
  • Country
  • XGN United States
  • GANX United States
  • Employees
  • XGN N/A
  • GANX N/A
  • Industry
  • XGN Medical Specialities
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • XGN Health Care
  • GANX Health Care
  • Exchange
  • XGN Nasdaq
  • GANX Nasdaq
  • Market Cap
  • XGN 33.9M
  • GANX 31.5M
  • IPO Year
  • XGN 2019
  • GANX 2021
  • Fundamental
  • Price
  • XGN $1.95
  • GANX $1.36
  • Analyst Decision
  • XGN Buy
  • GANX Strong Buy
  • Analyst Count
  • XGN 1
  • GANX 4
  • Target Price
  • XGN $7.00
  • GANX $8.25
  • AVG Volume (30 Days)
  • XGN 18.5K
  • GANX 546.9K
  • Earning Date
  • XGN 08-05-2024
  • GANX 08-08-2024
  • Dividend Yield
  • XGN N/A
  • GANX N/A
  • EPS Growth
  • XGN N/A
  • GANX N/A
  • EPS
  • XGN N/A
  • GANX N/A
  • Revenue
  • XGN $55,733,000.00
  • GANX N/A
  • Revenue This Year
  • XGN $7.16
  • GANX $1,009.10
  • Revenue Next Year
  • XGN $16.16
  • GANX N/A
  • P/E Ratio
  • XGN N/A
  • GANX N/A
  • Revenue Growth
  • XGN 20.12
  • GANX N/A
  • 52 Week Low
  • XGN $1.30
  • GANX $1.11
  • 52 Week High
  • XGN $2.99
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • XGN 57.19
  • GANX 42.31
  • Support Level
  • XGN $1.71
  • GANX $1.11
  • Resistance Level
  • XGN $1.97
  • GANX $1.40
  • Average True Range (ATR)
  • XGN 0.08
  • GANX 0.08
  • MACD
  • XGN 0.00
  • GANX 0.06
  • Stochastic Oscillator
  • XGN 91.31
  • GANX 94.03

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: